This article is more than 5 years old. Information may no longer be current.

Phaco, phacotrabeculectomy have similar long-term PCO rates

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DETROIT — No significant differences were found in the incidence of long-term posterior capsular opacification between phacoemulsification and phacotrabeculectomy, a study here found. Use of mitomycin C adjunctively was a protective factor against PCO in the phacotrabeculectomy group, as was the presence of diabetes mellitus in the overall patient group, the study authors said.

Researchers here retrospectively studied 100 eyes of 100 patients with cataracts who underwent phaco and posterior chamber IOL implantation and 100 eyes of 100 primary open-angle glaucoma patients with cataract who underwent phacotrabeculectomy and posterior chamber IOL implantation.

No significant difference in the rate of PCO requiring Nd:YAG capsulotomy was found between the phaco and phacotrabeculectomy groups. However, a significant difference in the rate of PCO was found between patients without diabetes mellitus and those diagnosed with the disease preoperatively (P = .016). A survival analysis showed patients in the phacotrab group who received mitomycin C had a higher survival rate than those who did not (P = .03).

The study is published in the American Journal of Ophthalmology.